StockData
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Corp. (KTTA) stock

KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.51+0.08 (+17.64%)

Close on Nov 18, 2026Market cap $17.07MP/E –Yield –

Pasithea Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Pasithea Therapeutics's price to sales ratio was 18.7× on Apr 28, 2023.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Apr 28, 202318.7×–

More Pasithea Therapeutics figures

See a number that looks wrong?